Electromed Shares Upgraded to Strong-Buy by StockNews.com

Electromed (NYSE:ELMD) has received an upgrade from StockNews.com, moving its rating from a "buy" to a "strong-buy". This change was announced in a research note released on Tuesday, signaling increased confidence in the company’s stock performance.

Stock Performance Overview

During trading on Tuesday, Electromed’s shares fell by 2.5%, reaching $29.20. The trading volume for the day was 186,912 shares, significantly higher than its average of 98,540 shares. Over the past year, the stock has experienced a low of $10.05 and a high of $35.56. Electromed’s market capitalization stands at $247.03 million, with a price-to-earnings (PE) ratio of 40.56 and a beta of 0.33, indicating a relatively stable stock. Currently, the company’s 50-day simple moving average is $31.13, and the two-hundred day moving average is $24.45.

Electromed reported its latest earnings results on November 12, showing earnings of $0.16 per share for the quarter, which exceeded the consensus estimate of $0.03 by $0.13. The company achieved a net margin of 11.34% and a return on equity of 15.32%, with total revenue of $14.67 million for the quarter.

Insider Activity

In another recent development, Director Andrew Summers sold 17,463 shares of Electromed on December 2 at an average price of $30.09, resulting in a transaction worth approximately $525,461.67. Following this sale, Summers retains 189,838 shares valued at over $5.7 million, although this represents an 8.42% decrease in his stake. This transaction was reported to the Securities & Exchange Commission, which can be reviewed on their website. Insiders currently hold 14% of the company's shares.

Institutional Investors' Stance

Recent modifications by hedge funds show a growing interest in Electromed. For instance, IFP Advisors Inc acquired a new stake worth about $59,000 in the fourth quarter. Additional investments came from Quantbot Technologies LP and Barclays PLC, with stakes valued at approximately $99,000 and $215,000 respectively. Other firms, such as Bailard Inc. and Wilmington Savings Fund Society FSB, also entered the fold with investments costing around $224,000 and $226,000 respectively. Together, institutional investors now own around 40.82% of Electromed's shares.

About Electromed

Electromed, Inc. specializes in developing, manufacturing, marketing, and selling airway clearance therapy products. They focus on high-frequency chest wall oscillation (HFCWO) therapy used in pulmonary care for patients of various ages, both in the United States and internationally. Their product lineup includes the SmartVest airway clearance system designed for patients with weakened pulmonary functions, affected by conditions such as bronchiectasis and cystic fibrosis, as well as issues like cerebral palsy and amyotrophic lateral sclerosis. Other offerings include the SmartVest SQL System and SmartVest Clearway System, which consists of an inflatable garment and air pulse generator. The company also provides SmartVest Connect, a wireless technology that links patients and physicians to monitor therapy and enhance treatment planning.

Electromed, Stocks, Upgrade